Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued enzalutamide beyond progression with abiraterone in chemotherapy-naive metastatic castration-resistant prostate cancer
2013-000722-54Phase 4Unknown
- Sponsor
- Pfizer
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of enzalutamide, abiraterone, prednisone and prednisolone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
enzalutamideabirateroneprednisoneprednisolone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-000722-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000722-54.